Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04969861
Title BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nektar Therapeutics

oral squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

oral cavity cancer

laryngeal squamous cell carcinoma

hypopharynx cancer


NKTR-214 + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA | ITA | FRA | AUT

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
GenesisCare USA Jacksonville Florida 32204 United States Details
Florida Cancer Affiliates - Ocala Ocala Florida 34474 United States Details
Methodist Cancer center Omaha Nebraska 68114 United States Details
Inova Schar Cancer Institute Fairfax Virginia 22031 United States Details
Chris O'Brien Lifehouse Hospital Camperdown New South Wales Australia Details
Universitätsklinikum Salzburg Salzburg Austria Details
Hôpital Saint-André Bordeaux Gironde France Details
Attikon University General Hospital Athens Attiki Greece Details
Hygeia Diagnostic and Therapeutic Centre of Athens Maroúsi Attiki Greece Details
University General Hospital of Larissa Larissa Greece Details
Bioclinic Thessaloniki (Galinos Clinic) Thessaloníki Greece Details
Rabin Medical Center Petah tikva Israel Details
ASST Degli Spedali Civili di Brescia Brescia Lombardia Italy Details
Universitair Medisch Centrum Utrecht Cancer Center - PPDS Utrecht Netherlands Details
National Cancer Centre Singapore Singapore Details
*Shaded cells indicate that there was no data available from for the field